In addition, studies also showed that CBL-B is required for the leukemogenesis mediated by BCR-ABL through the negative regulation of bone marrow homing [49] and that CML with the CBL-B mutation is resistant to imatinib [50]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.